Close

Professor David Moore

MBChB MD DTM&H MSc (Epi) FRCP

Professor
of Infectious Diseases and Tropical Medicine

Room
Room 308

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 (0)20 7927 2142

In my current position I have three roles - I lead a TB research group centred primarily in Lima, Peru; I am Course Director for the DTM&H; and I am Consultant in Infectious Diseases and Tropical Medicine at the Hospital for Tropical Diseases in London.

Four years after graduating from Birmingham Medical School in 1989 I found myself working at Hlabisa Hospital in rural Kwazulu-Natal in South Africa. It was here that my eyes were opened to tropical medicine and public health. On returning to the UK I was fortunate to get onto the North Thames ID training rotation culminating in a year at the Hospital for Tropical Diseases.

After a 2001/2002 Masters in Epidemiology at the school we moved to Lima, Peru with a Wellcome Trust Research Training Fellowship in Clinical Tropical Medicine to evaluate the rapid TB and MDRTB diagnostic test MODS (www.modsperu.org) in the laboratory of JHU Professor Bob Gilman at Universidad Peruana Caytano Heredia (http://www.upch.edu.pe/).

MODS has been transformed from an interesting research observation into a formally recognised rapid diagnostic test endorsed by WHO in 2010 and with further Wellcome support through a Career Development Fellowship we were able to evaluate the process of implementation of MODS into the Peruvian National TB Control Programme (NTP) and Regional Reference Laboratory Network. At $5.00 for an TB detection and MDR test available within 7 days MODS represents good value for money in this MDR high-burden setting.

The success of our research effort in Peru is largely a result of excellent collaborative links with the Peruvian NTP and with ID and chest physicians in the major Lima hospitals. Thus our work is integrated from the outset and only follows an agenda that is acceptable and prioritised in-country, maximising the likelihood of policy adoption at the end of the process.

Through enhanced MDR diagnosis we became interested in exposed household contacts and thus the conundrum of understanding latent TB infection. Our recent work suggests that perhaps only one third of people labelled as having "LTBI" by tuberculin skin test or IGRA actually have viable and thus true latency. Future work aims to define this more clearly.

Affiliations

Faculty of Infectious and Tropical Diseases
Department of Clinical Research

Centres

TB Centre

Teaching

My main teaching responsibility at LSHTM is as Course Director for the DTM&H (http://www.lshtm.ac.uk/prospectus/short/stmh.html); I am also a tutor for the MSc in Tropical Medicine and International Health and the MSc in Control of Infectious Diseases.

During my 7 years in Lima I was privileged to supervise and mentor a large number of extremely talented and dynamic science and medical undergraduates and postgraduates from the UK, Peru and the US who passed through our research unit. Their names are too numerous to mention but most of them feature on at least one and often two of the publications on our publication list.

My research group in Lima remains active and postgraduate students from LSHTM and elsewhere are welcomed, though a good command of Spanish is a prerequisite.

Research

My primary research interest is in control of tuberculosis and drug-resistant tuberculosis through innovative strategies for diagnosis of adult and paediatric TB, management of latent TB infection and active TB disease (drug-susceptible and drug-resistant), and institutional and domestic TB infection control.

MODS delivers rapid, low-cost diagnosis of MDR-TB but important by-products of this enhanced diagnostic testing include identification of a large number of MDR-exposed household contacts and individuals with isoniazid resistant (non-MDR) TB. My group is exploring transcriptomic responses to preventive therapy for contacts exposed to drug-susceptible TB with an eye to future evaluations of preventive therapy for MDR-exposed contacts. We are also working on development of a MDR contact registry to enhance capacity of programmes to identify and track MDR contacts and to create a ready-to-go line list of individuals eligible for MDR preventive therapy in the event that current ongonig trials identify an efficacious regimen.

We also have a growing interest in development of laboratory capacity through innovative laboratory design and application of portable containerized laboratories.

An expanding area of interest is control of bartonellosis (Oroya fever, Verruga Peruana) due to Bartonella bacilliformis; knowledge gaps in diagnosis, natural history, epidemiology, vector biology and therapeutics are amongst the major challenges for this neglected disease affecting impoverished Andean communities. We have started to grow a research collaboration with Peruvian academic and Ministry of Health partners in order to undertake a major programme of research with a view to development of an agenda for disease control and ultimately elimination.

In London, aligned with my clinical tropical medicine practice at the Hospital for Tropical Diseases (UCLH), we are leading operational research into implementation of screening for Chagas disease in Latin American migrants now living in the UK. We have established a UK Chagas Hub for clinicians, scientists and members of the Latin American community to come together to explore ways to optimise clinical pathways, raise awareness and undertake research. http://www.thehtd.org/chagasuk.aspx

Research Area
Diagnostics
Health services research
Pharmacokinetics
Discipline
Epidemiology
Microbiology
Operational research
Disease and Health Conditions
Infectious disease
Tuberculosis
Chagas Disease
Tropical diseases
Country
United Kingdom
Pakistan
Peru
Somalia
Uganda
South Africa
Region
Latin America & Caribbean (developing only)
Sub-Saharan Africa (developing only)

Selected Publications

Feasibility of an mobile application as a tool for multidrug-resistant tuberculosis contact monitoring in Peru.
Allen R; Calderón M; Moore DAJ; Gaskell KM; Curisinche-Rojas M; López S
2021
Revista peruana de medicina experimental y salud publica
Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis.
Calderwood CJ; Wilson JP; Fielding KL; Harris RC; Karat AS; Mansukhani R; Falconer J; Bergstrom M; Johnson SM; McCreesh N
2021
PLoS medicine
he population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study). A prospective nested study protocol in a randomised controlled trial.
Nyang'wa B; Kloprogg F; Moore D; Bustinduy A; Motta I; Berry C; Davies G
2021
BMJ Open
Genomic Signatures of Pre-Resistance in Mycobacterium tuberculosis
Ortiz AT; Coronel J; Vidal JR; Bonilla C; Moore D; Gilman R; Balloux F; Kon OM; Didelot X; Grandjean L
2021
Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease.
Pollara G; Turner CT; Rosenheim J; Chandran A; Bell LCK; Khan A; Patel A; Peralta LF; Folino A; Akarca A
2021
Science translational medicine
Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda.
Reza TF; Nalugwa T; Nantale M; Adams K; Fielding K; Nakaweesa A; Oyuku D; Nabwire S; Musinguzi J; Ojok C
2021
Contemporary clinical trials communications
Where will it end? Pathways to care and catastrophic costs following negative TB evaluation in Uganda.
Samuels THA; Shete PB; Ojok C; Nalugwa T; Farr K; Turyahabwe S; Katamba A; Cattamanchi A; Moore DAJ
2021
PloS one
See more Publications